Scarica l'app Stockscreener
203.08
4.00%
7.81
Pre-mercato:
204.00
0.92
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$195.27
Aprire:
$197.29
Volume 24 ore:
1.14M
Relative Volume:
0.76
Capitalizzazione di mercato:
$29.46B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
19.58
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
+2.25%
1M Prestazione:
+1.39%
6M Prestazione:
-20.52%
1 anno Prestazione:
-26.20%
Intervallo 1D:
$195.79
$203.58
Intervallo di 1 settimana:
$190.21
$203.58
Portata 52W:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
203.08 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
356.83 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
158.92 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.70 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.28 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Down 31%: Is there any chance of a rebound from ResMed shares? - The Motley Fool Australia
Is It Too Late to Buy ResMed Inc (RMD) After 4.0% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Resmed Inc (RMD) Institutional Confidence - TradingKey
ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching? - Kalkine
Resmed Inc (RMD) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock steadies as sleep-apnea demand supports earnings and growth - AD HOC NEWS
Resmed Inc (RMD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. (RMD) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Resmed Inc (RMD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Resmed Inc (RMD) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Earnings Dates, Call Summary & Reports - TipRanks
RESMED INC. R (RMEA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
ResMed stock advances on its latest earnings backdrop. - AD HOC NEWS
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
J.P. Morgan Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Catapult Sports, Hazer Group & ResMed - marketscreener.com
Resmed Inc (0KW4) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock trades near recent lows as investors assess obesity drug impact and earnings momentum - Ad-hoc-news.de
Resmed Inc (0KW4) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
ResMed (ASX:RMD) Moves Lower Today — Is the Sleep Apnoea Giant Still Worth Watching? - Kalkine
Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed stock steadies as investors weigh sleep apnea demand and recent earnings - Ad-hoc-news.de
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
ResMed stock steadies as sleep apnea demand supports earnings growth - Ad-hoc-news.de
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Moomoo
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE - marketscreener.com
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
ResMed stock trades near record territory as sleep apnea demand drives revenue growth - Ad-hoc-news.de
UBS lowers ResMed stock price target to $300 on valuation - Investing.com UK
UBS lowers ResMed stock price target to $300 on valuation By Investing.com - Investing.com Nigeria
ResMed stock trades near recent highs as sleep apnea demand supports growth - Ad-hoc-news.de
Can ResMed (ASX:RMD) Reignite Growth by Slimming Down? - Kalkine Media
ResMed sharpens focus with a strategic sale: The Shift Few Are Watching - Kalkine Media
ResMed Target Price Cut 10% to A$40.00/Share by Canaccord Genuity>RMD.AU - Moomoo
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief Australia: EQ Resources, ResMed Inc, BHP Group Ltd and more - Smartkarma
RMD stock holds after latest ResMed results - ad-hoc-news.de
ResMed stock steadies as investors weigh obesity drug impact and solid earnings base - Ad-hoc-news.de
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):